Literature DB >> 12003815

Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension.

Yasuko Iwakiri1, Ming-Hung Tsai, Timothy J McCabe, Jean-Philippe Gratton, David Fulton, Roberto J Groszmann, William C Sessa.   

Abstract

Akt, also known as protein kinase B, is a serine/threonine kinase. Akt becomes active when phosphorylated by the activation of receptor tyrosine kinases, G protein-coupled receptors, and mechanical forces such as shear stress. Studies in vitro have shown that Akt can directly phosphorylate endothelial nitric oxide (NO) synthase (eNOS) and activate the enzyme, leading to NO production. The aim of this study was to test the hypothesis that the phosphorylation of eNOS plays a role in the enhanced NO production observed in early portal hypertension. Male Sprague-Dawley rats were subjected to either sham or portal vein ligation (PVL), and mesenteric arterial beds were used for ex vivo perfusion studies. Mesenteric arterial beds from PVL rats had an approximately 60-70% decrease in response to methoxamine (an alpha(1)-agonist and vasoconstrictor) compared with the sham group (P < 0.01). When N(G)-monomethyl-L-arginine (a NOS inhibitor) was added to the perfusion, the difference in perfusion pressure between the two groups was abolished, suggesting that enhanced NO production in the PVL group blunted the response to the vasoconstrictor. The reduced responsiveness in PVL was not due to changes in eNOS expression but was due to an increase in enzyme-specific activity, suggesting posttranslational modification of eNOS. The phosphorylation of eNOS at Ser(1176) was significantly increased by twofold (P < 0.05) in the PVL group. Furthermore, PVL significantly increased Akt phosphorylation (an active form of Akt) by threefold (P < 0.05). When vessels were treated with wortmannin (10 nM) to block the phosphatidylinositol-3-OH-kinase/Akt pathway, NO-induced vasodilatation was significantly reduced. These results suggest that the phosphorylation of eNOS by Akt activates the enzyme and may be the first step leading to an initial increase in NO production in portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003815     DOI: 10.1152/ajpheart.00675.2001

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  23 in total

1.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

2.  Akt signaling in platelets and thrombosis.

Authors:  Donna S Woulfe
Journal:  Expert Rev Hematol       Date:  2010-02       Impact factor: 2.929

3.  Vascular biology and pathobiology of the liver: Report of a single-topic symposium.

Authors:  Yasuko Iwakiri; Matthew Grisham; Vijay Shah
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

Review 4.  Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Liver Int       Date:  2011-07-05       Impact factor: 5.828

Review 5.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

6.  Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase.

Authors:  Ru-Jeng Teng; Jianhai Du; Hao Xu; Ivane Bakhutashvili; Annie Eis; Yang Shi; Kirkwood A Pritchard; Girija G Konduri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-27       Impact factor: 5.464

7.  Systemic and pulmonary hemodynamics in patients with extrahepatic portal vein obstruction is similar to compensated cirrhotic patients.

Authors:  Sanjeev Kumar Jha; Ashish Kumar; Barjesh Chander Sharma; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2008-12-06       Impact factor: 6.047

8.  Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy.

Authors:  Camila Marques; Francielli Licks; Ingrid Zattoni; Beatriz Borges; Luiz Eduardo Rizzo de Souza; Claudio Augusto Marroni; Norma Possa Marroni
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

Review 9.  The portal hypertension syndrome: etiology, classification, relevance, and animal models.

Authors:  Jaime Bosch; Yasuko Iwakiri
Journal:  Hepatol Int       Date:  2017-10-24       Impact factor: 6.047

10.  Variations of brain endothelial nitric oxide synthase concentration in rat and mouse cortex.

Authors:  R Kenneth Czambel; Alexander Kharlamov; Stephen C Jones
Journal:  Nitric Oxide       Date:  2009-12-03       Impact factor: 4.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.